- New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.
- Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade
- Construction will begin in fall 2025 with the site expected to be fully operational in 2027
- Furthers AbbVie's long-term commitment to the U.S. expanding the company's North Chicago workforce and critical manufacturing capabilities
NORTH CHICAGO, Ill., Aug. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S. This expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity.
Active pharmaceutical ingredient manufacturing is a complex and multi-step process that involves producing the active components responsible for the therapeutic effects of medications. The new North Chicago API facility will expand AbbVie's chemical synthesis capabilities in the U.S. supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines.